[PDF][PDF] Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast …

A Musolino, N Naldi, B Bortesi, D Pezzuolo… - Journal of Clinical …, 2008 - academia.edu
A Musolino, N Naldi, B Bortesi, D Pezzuolo, M Capelletti, G Missale, D Laccabue, A Zerbini…
Journal of Clinical Oncology, 2008academia.edu
Purpose The anti–HER-2/neu monoclonal antibody trastuzumab has been shown to engage
both activatory (fragment C receptor [FcR] IIIa; FcRIIa) and inhibitory (FcRIIb) antibody
receptors and FcR polymorphisms have been identified that may affect the antibody-
dependent cell-mediated cytotoxicity (ADCC) of natural-killer cells/monocytes. In this study,
we tested whether FcR polymorphisms are associated with clinical outcome of patients with
breast cancer who received trastuzumab.
Purpose
The anti–HER-2/neu monoclonal antibody trastuzumab has been shown to engage both activatory (fragment C receptor [FcR] IIIa; FcRIIa) and inhibitory (FcRIIb) antibody receptors and FcR polymorphisms have been identified that may affect the antibody-dependent cell-mediated cytotoxicity (ADCC) of natural-killer cells/monocytes. In this study, we tested whether FcR polymorphisms are associated with clinical outcome of patients with breast cancer who received trastuzumab.
academia.edu